Business Description
Zai Lab Ltd
NAICS : 325412
SIC : 2834
ISIN : US98887Q1040
Share Class Description:
ZLAB: ADR Repr 1 ShsCompare
Compare
Traded in other countries / regions
ZLAB.USA09688.Hong KongZLAB.Mexico1ZLB.Germany IPO Date
2017-09-20Description
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.9 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | -0.42 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 2.39 | |||||
| Beneish M-Score | -1.6 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 63.6 | |||||
| 3-Year EBITDA Growth Rate | -3.7 | |||||
| 3-Year EPS without NRI Growth Rate | 3 | |||||
| 3-Year FCF Growth Rate | 9.8 | |||||
| 3-Year Book Growth Rate | -15 | |||||
| Future 3-5Y Total Revenue Growth Rate | 53.97 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.28 | |||||
| 9-Day RSI | 47.6 | |||||
| 14-Day RSI | 47.33 | |||||
| 6-1 Month Momentum % | 40.96 | |||||
| 12-1 Month Momentum % | 4.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.01 | |||||
| Quick Ratio | 2.87 | |||||
| Cash Ratio | 2.15 | |||||
| Days Inventory | 116.07 | |||||
| Days Sales Outstanding | 57.63 | |||||
| Days Payable | 280.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.5 | |||||
| Shareholder Yield % | -1.78 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 63.17 | |||||
| Operating Margin % | -93.36 | |||||
| Net Margin % | -76.14 | |||||
| FCF Margin % | -61.46 | |||||
| ROE % | -35.53 | |||||
| ROA % | -26.86 | |||||
| ROIC % | -191.44 | |||||
| ROC (Joel Greenblatt) % | -287.11 | |||||
| ROCE % | -38.79 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.38 | |||||
| PB Ratio | 3.96 | |||||
| Price-to-Tangible-Book | 4.26 | |||||
| EV-to-EBIT | -7.76 | |||||
| EV-to-Forward-EBIT | -6.15 | |||||
| EV-to-EBITDA | -8.05 | |||||
| EV-to-Forward-EBITDA | -6.15 | |||||
| EV-to-Revenue | 6.74 | |||||
| EV-to-Forward-Revenue | 3.25 | |||||
| EV-to-FCF | -11.15 | |||||
| Price-to-Net-Current-Asset-Value | 4.88 | |||||
| Price-to-Net-Cash | 8.87 | |||||
| Earnings Yield (Greenblatt) % | -12.89 | |||||
| FCF Yield % | -7.63 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ZLAB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zai Lab Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 355.748 | ||
| EPS (TTM) ($) | -2.7 | ||
| Beta | 0.8 | ||
| Volatility % | 50.82 | ||
| 14-Day RSI | 47.33 | ||
| 14-Day ATR ($) | 1.269434 | ||
| 20-Day SMA ($) | 27.5345 | ||
| 12-1 Month Momentum % | 4.47 | ||
| 52-Week Range ($) | 13.48 - 36.6 | ||
| Shares Outstanding (Mil) | 108.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zai Lab Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zai Lab Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zai Lab Ltd Frequently Asked Questions
What is Zai Lab Ltd(ZLAB)'s stock price today?
The current price of ZLAB is $26.89. The 52 week high of ZLAB is $36.60 and 52 week low is $13.48.
When is next earnings date of Zai Lab Ltd(ZLAB)?
The next earnings date of Zai Lab Ltd(ZLAB) is 2025-02-27 Est..
Does Zai Lab Ltd(ZLAB) pay dividends? If so, how much?
Zai Lab Ltd(ZLAB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers